Viral hepatitis more deadly than HIV in Europe

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.
 
GBD 2010 is the most recent version of a large epidemiological study funded by the Bill and Melinda Gates Foundation and coordinated by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
 
In the EU, in 2010, there were more than 10 times as many deaths due to viral hepatitis as there were HIV-attributable deaths. Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) are estimated to have caused nearly 90,000 deaths that year in the EU (HCV nearly 57,000 deaths, HBV nearly 31,000 deaths), while there were just over 8,000 deaths from HIV/AIDS.
 
Presenting these thought-provoking figures, EASL's Vice-Secretary Dr. Laurent Castera from the department of Hepatology, Hôpital Beaujon in Paris said: "GBD 2010 is making a critical contribution to our understanding of present and future health priorities for countries and the global community. Although HIV/AIDS undeniably remains a key global health priority, the higher mortality from viral hepatitis than from HIV/AIDS in the EU means that hepatitis B and C must clearly now be counted among the top global and local priorities for health."
 
Source: European Association for the Study of the Liver
 


[ Прочети още... ]

Публикувана от rosen -вторник, 15 април 2014 - 04:28:59изглед за печат

 
Лекарства, използвани при трансплантация, може да помогнат за излекуване на ХИВ инфекцията

Според ново проучване може да бъде прилагана нова терапия срещу човешкия имунодефицитен вирус чрез използването на медикаменти, които нормално се прилагат с цел предотвратяване отхвърляне на трансплантиран орган
 
В момента за лечението на ХИВ се прилагат антиретровирусни препарати, които блокират репликацията на вируса и намаляват вредите, които той оказва върху имунната система.

Антиретровирусните средства обаче не са ефективни на 100%, те са скъпи и могат да доведат до наличието на редица странични ефекти. Експерименталните изследвания търсят алтернативни стратегии за управление, предотвратяване и дори евентуално излекуване на ХИВ.

Новото изследване, водено от изследователите в Университета на Калифорния, Сан Франциско, се отнася до научни открития от 2009 г., които изглеждаха обещаващи за излекуването на пациент с помощта на трансплантация на хемопоетични стволови клетки.

Ръководителят на изследването д-р Стивън Дийкс изтъква като недостатък на наличните и прилагани досега терапии, невъзможността за откриване на скрити вируси. Така те се проявяват в един по-късен етап на болестта, в който лечението е трудно и слабо ефективно.
Екипът, провеждащ изследването, смята, че прилагането на имуносупресивна терапия, може да неутрализира влиянието на тези „скрити“ вируси, като по този начин няма да бъде създадена гостоприемна среда за развитието на ХИВ.
 
Учените, проследяват 91 бъбречни трансплантации, при пациенти, които са ХИВ позитивни, в период от 3 години след трасплантацията.
 
Източник: Wiley

Публикувана от rosen -вторник, 08 април 2014 - 09:27:54изглед за печат

 
Transplant drugs may help wipe out persistent HIV infections

New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV.
 
The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS.
 
Despite the effectiveness of antiviral therapies at suppressing HIV, the virus still persists indefinitely at low levels in infected patients who are diligent about taking their medications.
 
"Current therapies fail to cure the disease as they do not attack those viruses that remain hidden within the immune system," said Steven Deeks, MD, of the University of California, San Francisco. Researchers suspect that inflammation in the body in response to HIV infection may create an environment that supports this viral persistence.
 
Dr. Deeks and his colleagues wondered whether immunosuppressant therapy could reduce such inflammation and therefore help defeat HIV. To investigate, the team looked at how HIV infection is affected by immunosuppressants that are commonly taken by kidney transplant recipients to reduce their risk of rejection.
 
The analysis included 91 recipients who were followed for a median of 3.2 years post-transplant.
 
Source: Wiley


[ Прочети още... ]

Публикувана от rosen -вторник, 08 април 2014 - 08:15:25изглед за печат

 
Event at CPD to train youth advocates

The Alliance and its Link Up consortium partners are training youth advocates to get their HIV & SRHR-related needs on the post-2015 agenda during the 47th Commission on Population and Development this week.
 
This year's theme is the “Assessment of the status of implementation of the Programme of Action of the International Conference on Population and Development”.
 
In keeping with the theme, the findings of a global review of the Programme of Action - which lay bare the strong links between sexual and reproductive health and rights (SRHR), HIV and human and economic development - will be presented at the meeting.
 
To coincide with the CPD meeting, global policy partners in the Link Up project - along with Resurj, the International Women's Health Coalition, the International Federation of Medical Students' Associations and UNAIDS - are organising a side event on 8 April in New York.
 
The session aims to strengthen the capacity of young people to advocate for greater attention to their HIV and SRHR-related needs in the post-2015 framework.
 
 
 

Публикувана от rosen -вторник, 08 април 2014 - 07:38:42изглед за печат

 
Similarities between HIV/AIDS, opioid addiction epidemics

There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction -- ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment.
 
These are the findings of a comparative review of HIV/AIDS and addiction by researchers Josiah D. Rich, M.D., M.P.H., director of the Center for Prisoner Health and Human Rights, based at The Miriam Hospital; Traci C. Green, Ph.D., MSc, Department of Emergency Medicine at Rhode Island Hospital and assistant professor of Emergency Medicine and Epidemiology at the Warren Alpert Medical School of Brown University; and lead author Sarah E. Wakeman, M.D., Department of Medicine and Center for Community Health Improvement, Massachusetts General Hospital.
 
The paper is published online in advance of print in the American Journal of Medicine.
 
"Deaths documented by the Centers for Disease Control and Prevention have been on the rise, and that profile bears a striking resemblance to the beginning stages of the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic," said Rich. "There are lessons learned from the HIV/AIDS epidemic that should be heeded and should drive a parallel response to today's crisis: addiction."
 
In the paper, "From Documenting Death to Comprehensive Care: Applying Lessons from the HIV/AIDS Epidemic to Addiction," researchers detail how the HIV/AIDS epidemic spurred a novel public health approach centered on human rights. That included biomedical breakthroughs and life-saving treatment, and community advocacy and activism played key roles. Fast forward 30 years and the global response to HIV/AIDS has attracted an unprecedented commitment of resources and international aid, and there are predictions for its end. Researchers assert that a parallel response is needed in response to the epidemic of addiction.
 
Source: Lifespan
 


[ Прочети още... ]

Публикувана от rosen -петък, 04 април 2014 - 04:52:01изглед за печат

 
Отиди на страница       >>